The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2025A Meta-Analysis of Single Nucleus Allele Specific Expression to Investigate Parkinson's Disease
Study Rationale: We will study “allele-specific expression” to understand how DNA variants relevant to Parkinson’s disease impact the expression of genes. By looking in each cell, we can check whether...
-
Research Grant, 2025Identifying and Pilot Testing Best Practices for Sharing Amyloid PET Research Information with Individuals Living with Lewy Body Diseases
Study Rationale: Biomarkers are tests that measure something about a person’s health. Research studies often include biomarkers, but research participants may or may not receive the results. This...
-
Research Grant, 2026Multiscale Measurement of O-GlcNAc Changes in Parkinson’s Disease
Study Rationale:
Directly targeting the toxic aggregation of α-synuclein by drugs is very challenging. However, this protein is modified by different chemical groups that have the...
-
Spring 2025 RFA: Molecular MRI Biomarker Program, 2026Mapping Mitochondrial Dysfunction in Parkinson’s Disease Using 15N-Magnetic Resonance of Nicotinamide Metabolism (MiND15)
Study Rationale:
In Parkinson’s disease, one of the earliest problems in the brain is a failure of mitochondria—tiny structures that produce energy for cells. This energy failure happens before many...
-
Spring 2025 RFP: Accelerating Biological Understanding and Therapeutic Translation for PD- Biology, 2026Bidirectional Genome-wide CRISPRi/a Screening Using Ratiometric GCase Substrates to Identify Genetic Modulators of Lysosomal GCase Activity
Study Rationale:
Mutations in the gene GBA1, are the most common genetic risk factor for Parkinson Disease (PD). Mutations in GBA1 lead to malfunctioning of the protein glucocerebrosidase, which acts...
-
Spring 2025 RFP: Accelerating Biological Understanding and Therapeutic Translation for PD- Biology, 2026Deciphering Intracellular Pathways Altered by LRRK2 Kinase Activity and Phospho-RAB Effector Function
Study Rationale:
Gain-of-function mutations in LRRK2 cause familial Parkinson’s disease (PD) and increase the risk of developing the sporadic form of the disease. However, how...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.